Market capitalization | $420.00k |
Enterprise Value | $-5.70m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.63 |
P/B ratio (TTM) P/B ratio | 0.05 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.60m |
Free Cash Flow (TTM) Free Cash Flow | $-9.02m |
Cash position | $6.40m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast ENDRA Life Sciences Inc.:
1 Analyst has issued a forecast ENDRA Life Sciences Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.24 -0.24 |
11%
11%
|
|
EBITDA | -9.36 -9.36 |
24%
24%
|
EBIT (Operating Income) EBIT | -9.60 -9.60 |
24%
24%
|
Net Profit | -9.57 -9.57 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
Head office | United States |
CEO | Alexander Tokman |
Employees | 21 |
Founded | 2007 |
Website | www.endrainc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.